P. Pronzato

6.9k total citations · 1 hit paper
231 papers, 4.4k citations indexed

About

P. Pronzato is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P. Pronzato has authored 231 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 61 papers in Cancer Research. Recurrent topics in P. Pronzato's work include Cancer Treatment and Pharmacology (77 papers), Breast Cancer Treatment Studies (53 papers) and Estrogen and related hormone effects (30 papers). P. Pronzato is often cited by papers focused on Cancer Treatment and Pharmacology (77 papers), Breast Cancer Treatment Studies (53 papers) and Estrogen and related hormone effects (30 papers). P. Pronzato collaborates with scholars based in Italy, United States and United Kingdom. P. Pronzato's co-authors include Lucia Del Mastro, Matteo Lambertini, Paolo Bruzzi, Gianfilippo Bertelli, Pierfranco Conté, Alessia Levaggi, Francesca Poggio, S. Giraudi, Claudia Bighin and R. Rosso and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

P. Pronzato

223 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

2022 154 citations Carlo Genova, Chiara Dellepiane et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Pronzato Italy	32	2.5k	1.1k	887	884	731	231	4.4k
Gloria Broadwater United States	42	3.1k 1.2×	1.8k 1.6×	286 0.3×	1.0k 1.1×	1.2k 1.6×	182	6.2k
Teresa Gamucci Italy	28	2.3k 0.9×	723 0.6×	482 0.5×	688 0.8×	827 1.1×	128	3.5k
Francesco Perrone Italy	38	3.6k 1.4×	870 0.8×	520 0.6×	1.8k 2.1×	1.1k 1.5×	188	5.9k
Sercan Aksoy Türkiye	27	1.7k 0.7×	430 0.4×	403 0.5×	780 0.9×	554 0.8×	284	3.6k
Jean‐Paul Guastalla France	31	2.2k 0.9×	674 0.6×	284 0.3×	495 0.6×	621 0.8×	109	3.7k
Séamus O’Reilly Ireland	35	3.9k 1.5×	756 0.7×	459 0.5×	1.2k 1.4×	1.4k 1.9×	227	6.8k
Francesco Boccardo Italy	39	3.1k 1.2×	2.3k 2.1×	412 0.5×	2.0k 2.3×	1.4k 1.9×	273	6.8k
John T. Soper United States	51	1.9k 0.8×	525 0.5×	1.3k 1.5×	826 0.9×	1.3k 1.8×	191	8.3k
Stefania Gori Italy	30	2.0k 0.8×	694 0.6×	507 0.6×	897 1.0×	680 0.9×	180	3.5k
Janine Mansi United Kingdom	41	3.5k 1.4×	1.2k 1.0×	294 0.3×	2.3k 2.5×	1.0k 1.4×	123	6.5k

Countries citing papers authored by P. Pronzato

Since Specialization

Citations

This map shows the geographic impact of P. Pronzato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Pronzato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Pronzato more than expected).

Fields of papers citing papers by P. Pronzato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Pronzato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Pronzato. The network helps show where P. Pronzato may publish in the future.

Co-authorship network of co-authors of P. Pronzato

This figure shows the co-authorship network connecting the top 25 collaborators of P. Pronzato. A scholar is included among the top collaborators of P. Pronzato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Pronzato. P. Pronzato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fontana, Vincenzo, et al.. (2023). A Descriptive Study of Repeated Hospitalizations and Survival of Patients with Metastatic Melanoma in the Northern Italian Region during 2004–2019. Current Oncology. 30(6). 5266–5278.

Boutros, Andrea, Roberta Carosio, Francesco Spagnolo, et al.. (2023). The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors. Immuno-Oncology Technology. 20. 100408–100408. 3 indexed citations

Boutros, Andrea, Enrica T. Tanda, Fabio Catalano, et al.. (2023). Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. European Journal of Cancer. 188. 64–79. 24 indexed citations

Zullo, Lodovica, Giovanni Rossi, Simona Coco, et al.. (2022). Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. Expert Opinion on Biological Therapy. 22(10). 1259–1273. 17 indexed citations

Tagliamento, Marco, Elisa Agostinetto, Marco Bruzzone, et al.. (2021). Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 163. 103365–103365. 44 indexed citations

Zullo, Lodovica, Giovanni Rossi, Chiara Dellepiane, et al.. (2021). Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Focus on Challenging Populations. Immunotherapy. 13(6). 509–525. 3 indexed citations

Rossi, Giovanni, Alessandro Russo, Marco Tagliamento, et al.. (2020). Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers. 12(5). 1125–1125. 48 indexed citations

Rossi, Giovanni, Alessandro Fedeli, Gianluca Ficarra, et al.. (2020). Radiomic Detection of EGFR Mutations in NSCLC. Cancer Research. 81(3). 724–731. 78 indexed citations

Rossi, Giovanni, Alessandro Russo, Marco Tagliamento, et al.. (2020). Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. 8(6). 300–317. 1 indexed citations

10.

Bighin, Claudia, Béatrice Dozin, Francesca Poggio, et al.. (2017). Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. Oncotarget. 8(27). 44800–44810. 4 indexed citations

11.

Poggio, Francesca, Marcello Ceppi, Matteo Lambertini, et al.. (2017). Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. The Breast. 33. 104–108. 17 indexed citations

12.

Puglisi, Fabio, et al.. (2015). Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. Cancer Treatment Reviews. 43. 36–49. 7 indexed citations

13.

Rossi, Giovanni, Roberta Iadarola, Matteo Lambertini, et al.. (2015). The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer. Annals of Oncology. 26. vi8–vi8. 1 indexed citations

14.

Aapro, Matti, Volker Moebus, Ulrike Nitz, et al.. (2014). Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Annals of Oncology. 26(4). 688–695. 21 indexed citations

15.

Arpino, Grazia, Daniele Generali, Anna Sapino, et al.. (2013). Gene expression profiling in breast cancer: A clinical perspective. The Breast. 22(2). 109–120. 57 indexed citations

16.

Mastro, Lucia Del, Matteo Lambertini, Claudia Bighin, et al.. (2012). Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Review of Anticancer Therapy. 12(11). 1391–1405. 19 indexed citations

17.

Mastro, Lucia Del, S. Giraudi, Alessia Levaggi, & P. Pronzato. (2011). Medical approaches to preservation of fertility in female cancer patients. Expert Opinion on Pharmacotherapy. 12(3). 387–396. 25 indexed citations

18.

Gennari, Alessandra, Maria Pia Sormani, P. Pronzato, et al.. (2007). HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. JNCI Journal of the National Cancer Institute. 100(1). 14–20. 258 indexed citations

19.

Grossi, Francesco, Carlotta Defferrari, Orazio Vinante, et al.. (2007). B2-07: Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach. Journal of Thoracic Oncology. 2(8). S339–S339. 2 indexed citations

20.

Venturini, Marco, Lucia Del Mastro, Enrico Aitini, et al.. (2005). Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. JNCI Journal of the National Cancer Institute. 97(23). 1724–1733. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact